Eurofins Scientific

Oligonucleotides Global Markets Report 2024: Historical Market Revenue Data from 2020 to 2022, Estimates for 2023, and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, General Health, Health, Genetics, Pharmaceutical, Diagnosis, Cytomegalovirus retinitis, PCR, Eurofins Scientific, Thermo Fisher Scientific, Disease, Oligonucleotide, CMV, ESG, Integration, Estimation, Research, RNA, DNA, Cancer, Competition, Infection, Agilent Technologies, Hepatitis, Spinal cord, In situ hybridization, Therapy, USD, FDA, Liver, Polymerase chain reaction, Fine chemical

The Global Oligonucleotides Market was valued at USD 7 Billion in 2023, and is expected to reach USD 11.7 Billion by 2028, rising at a CAGR of 11.00%.

Key Points: 
  • The Global Oligonucleotides Market was valued at USD 7 Billion in 2023, and is expected to reach USD 11.7 Billion by 2028, rising at a CAGR of 11.00%.
  • This report covers the worldwide market for oligonucleotide synthesis, which consists of four main product types: oligonucleotide drugs, synthesized oligos, equipment and reagents, and services.
  • Based on application, the market for oligonucleotide synthesis is divided into research diagnostics and therapeutics.
  • The report also covers approved drugs, the oligonucleotide synthesis process, innovative research, opportunities within the market and profiles of leading companies in the oligonucleotide synthesis industry.

ColdZyme® certified under the new EU medical device regulation (MDR)

Retrieved on: 
Monday, March 11, 2024
Certification, Infection, MDD, Sore throat, History, Classification, Virus, Ill, MDR, Eurofins Scientific, Safety, Trypsin, Medical device

Eurofins, a European approved notified body for medical devices, has certified the ColdZyme® product line MDR (class III) according to the European Union medical device regulation.

Key Points: 
  • Eurofins, a European approved notified body for medical devices, has certified the ColdZyme® product line MDR (class III) according to the European Union medical device regulation.
  • MDR replaces the previous EU regulation MDD and imposes stricter requirements on evidence of clinical validity, safety design, and market surveillance.
  • ColdZyme is one of the first flu- and cold products to be certified under the new regulation.
  • "This certification process has meant extensive review of our quality processes and product data in accordance with the medical device legislation.

Europe Medical Diagnostics Market Insights Report 2024-2028 with Competitive Analysis of Labcorp, Quest Diagnostics, Sonic Healthcare, Eurofins Scientific, Synlab and Medicover - ResearchAndMarkets.com

Retrieved on: 
Friday, March 8, 2024
Medical Devices, Health, Pandemic, Coagulation, POC, Sonic Healthcare, Growth, Immunoassay, Government, Urbanization, Clinical chemistry, Eurofins Scientific, Attention, COVID-19, Quest Diagnostics, Hematology, Medicine, Infection, Diagnosis, Labcorp, IVD, Medical device

The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
  • European medical diagnostics market is expected to reach US$109.91 billion in 2028, growing at a CAGR of 5.69%, for the time period of 2024-2028.
  • The report provides a comprehensive analysis of the European Medical Diagnostics Market.
  • The company profiles of leading players (Labcorp, Quest Diagnostics, Sonic Healthcare, Eurofins Scientific, Synlab and Medicover) are also presented in detail.

Sustainability Roundtable, Inc Announces 2023 SBER Awards

Retrieved on: 
Tuesday, December 19, 2023
Teradyne, Sustainable business, Eurofins Scientific, Multimedia, PTC, GHG, VPPA, Electricity, Carbon accounting, Thermo Fisher Scientific, Science, Covenant Baptist Theological Seminary, The Dupont Circle Hotel, Sustainability, Corporation, TMO, Automation, Renewable energy

BOSTON, Dec. 19, 2023 /PRNewswire/ -- Sustainability Roundtable, Inc. (SR Inc), a leader in strategic advisory & support as a service, celebrates its 2023 Sustainable Business & Enterprise Roundtable (SBER) award recipients. Thermo Fisher Scientific, Inc. received the SBER Outstanding Leader of 2023 award, Debra Pulpi at Teradyne, Inc. was awarded SBER Outstanding Executive of 2023, and PTC, Inc. received the SBER Most Improved Corporate Leader of 2023 award. SR Inc announced this year's recipients at its Year-End Executive Symposium hosted at the Dupont Circle Hotel in Washington D.C. on December 7, 2023, as it released proprietary best-practice guidance and tools to Member-Clients on sustainability strategy leadership, global corporate decarbonization, and climate-related mandatory reporting.

Key Points: 
  • BOSTON, Dec. 19, 2023 /PRNewswire/ -- Sustainability Roundtable, Inc. (SR Inc) , a leader in strategic advisory & support as a service, celebrates its 2023 Sustainable Business & Enterprise Roundtable (SBER) award recipients.
  • Thermo Fisher Scientific, Inc. received the SBER Outstanding Leader of 2023 award, Debra Pulpi at Teradyne, Inc. was awarded SBER Outstanding Executive of 2023, and PTC, Inc. received the SBER Most Improved Corporate Leader of 2023 award.
  • SR Inc recognized Thermo Fisher Scientific (NASDAQ: TMO), the world leader in serving science, as the SBER Outstanding Leader of 2023, for its leadership in renewable energy and across all aspects of corporate sustainability.
  • This innovative value chain-aligned procurement was supported by SR Inc's NZCB and championed by Matthew Yamatin, Thermo Fisher's Sustainability Program Director.

Thermo Fisher Scientific Establishes 2030 Renewable Electricity Goal and Solar Power Purchase Agreement with ib vogt

Retrieved on: 
Wednesday, December 6, 2023
Utilities, Environment, Alternative Energy, Green Technology, Energy, Research, Science, Carbon, Thermo Fisher Scientific, NYSE, Carbon neutrality, TMO, Mindful Scientific Inc., VPPA, Silent Scope 2, SMI, Carbon accounting, Electricity, Renewable energy, Management, Eurofins Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a 15-year virtual power purchasing agreement (VPPA) with international solar developer ib vogt .

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a 15-year virtual power purchasing agreement (VPPA) with international solar developer ib vogt .
  • Thermo Fisher’s 91-megawatt portion of the Serbal solar project will deliver approximately 192,000 megawatt hours of renewable electricity annually.
  • Eurofins Scientific , a global leader in bioanalytical testing, collaborated in the aggregated deal for a 36-megawatt portion of the project.
  • “We have taken a novel, value-chain-based approach in working with Thermo Fisher Scientific, as a supplier and partner, to reduce our Scope 2 emissions caused by electricity consumption.

Eurofins Scientific Announces the Acquisition of Labor 3, Further Expanding Its Offering to the Food and Feed Market in Brazil and the Presence of Eurofins Laboratories in Latin America

Retrieved on: 
Thursday, November 16, 2023
Research, Other Health, General Health, Hispanic, Pharmaceutical, Consumer, Technology, Food, Beverage, Retail, Clinical Trials, Science, Health, Food Tech, Acquisition, Labour, Genomics, Life, Laboratory, Pharmacology, Food industry, Food safety, LATAM, Environment, Pharmaceutical industry, Eurofins Scientific

The acquisition of Labor 3 further expands the Eurofins network of companies’ presence in Latin America, adding to Eurofins laboratories in 5 LATAM countries operating in the fields of the food, agroscience, genomics, environment, pharmaceutical, cosmetic product testing and clinical diagnostics.

Key Points: 
  • The acquisition of Labor 3 further expands the Eurofins network of companies’ presence in Latin America, adding to Eurofins laboratories in 5 LATAM countries operating in the fields of the food, agroscience, genomics, environment, pharmaceutical, cosmetic product testing and clinical diagnostics.
  • This acquisition will specifically strengthen the Eurofins network’s support to the food industry in Brazil, through the provision of tests, consulting and supporting evaluation across the entire food production chain, with the highest quality standards and turnaround time.
  • Known as Eurofins Labor 3 going forward, the laboratory represents the fifth Eurofins Food and Feed Testing laboratory in Brazil.
  • The origins of Eurofins’ presence in Brazil dates back to 2001, when Eurofins Genescan established its presence in Brazil, setting up an office in São Paulo/SP, shortly followed by the opening of a laboratory.

Eurofins Scientific Announces the Acquisition of Quasfar, Establishing a Presence in Colombia and Expanding the Presence of Eurofins Laboratories in Latin America

Retrieved on: 
Thursday, November 16, 2023
Other Health, Pharmaceutical, Other Natural Resources, Agriculture, Natural Resources, Fitness & Nutrition, Cosmetics, Retail, Science, Veterinary, Biotechnology, Health, Other Science, Acquisition, Good laboratory practice, Food, History, Life, Laboratory, Pharmacology, Technical report, LATAM, Environment, TAT, Pharmaceutical industry, Fine chemical, Eurofins Scientific

Known as Eurofins Quasfar going forward, the laboratory represents the first Eurofins laboratory in Colombia and is a leading pharmaceutical, veterinary and cosmetic product testing laboratory, with over 26 years of experience, employing over 100 employees.

Key Points: 
  • Known as Eurofins Quasfar going forward, the laboratory represents the first Eurofins laboratory in Colombia and is a leading pharmaceutical, veterinary and cosmetic product testing laboratory, with over 26 years of experience, employing over 100 employees.
  • Based in Bogotá, Colombia, the 1,680 m² laboratory is equipped with state-of-the-art testing equipment, technology and information platforms and systems, and is certified in Good Laboratory Practices for pharmaceutical quality control laboratories, under the guidelines of WHO Technical Report Series, No.
  • The origins of Eurofins’ presence in Brazil dates back to 2001, when Eurofins Genescan established its presence in Brazil, setting up an office in São Paulo/SP, shortly followed by the opening of a laboratory.
  • 900 laboratories in 61 countries, Eurofins offers a portfolio of over 200,000 analytical methods.

In Vitro Toxicology Testing Market Worth $17.1 billion | MarketsandMarkets

Retrieved on: 
Friday, October 27, 2023
MEA, Creative Biolabs, Eurofins Scientific, Pharmacology, Promega, Catalent, Patent, Intertek, Islamic finance products, services and contracts, Food, Charles River Laboratories, LATAM, Toxicology, Genetics, Absorption, Acquisition, Tissue engineering, Maintenance, Research, Protein, Phototoxicity, Software, Metabolism, Drug development, SGS, Growth, Thermo Fisher Scientific, Marketing, Merck Group, Agilent Technologies, Animal, Gene, Corrosion, Safety, Investment, Labcorp, Toxicity, Chemical safety, ADME, Medical device, Pharmaceutical industry, Fine chemical

By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services.

Key Points: 
  • By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services.
  • In 2022, the ADME segment accounted for the largest share of the in vitro toxicology testing market.
  • The pharmaceutical & biopharmaceutical segment accounted for the largest share of the industry segment in the in vitro toxicology testing market in 2022.
  • In 2022, the pharmaceutical & biopharmaceutical industry segment accounted for the largest share of the in vitro toxicology testing market.

In Vitro Toxicology Testing Market Worth $17.1 billion | MarketsandMarkets

Retrieved on: 
Friday, October 27, 2023
MEA, Creative Biolabs, Eurofins Scientific, Pharmacology, Promega, Catalent, Patent, Intertek, Islamic finance products, services and contracts, Food, Charles River Laboratories, LATAM, Toxicology, Genetics, Absorption, Acquisition, Tissue engineering, Maintenance, Research, Protein, Phototoxicity, Software, Metabolism, Drug development, SGS, Growth, Thermo Fisher Scientific, Marketing, Merck Group, Agilent Technologies, Animal, Gene, Corrosion, Safety, Investment, Labcorp, Toxicity, Chemical safety, ADME, Medical device, Pharmaceutical industry, Fine chemical

By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services.

Key Points: 
  • By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services.
  • In 2022, the ADME segment accounted for the largest share of the in vitro toxicology testing market.
  • The pharmaceutical & biopharmaceutical segment accounted for the largest share of the industry segment in the in vitro toxicology testing market in 2022.
  • In 2022, the pharmaceutical & biopharmaceutical industry segment accounted for the largest share of the in vitro toxicology testing market.

The Global In Vitro Toxicology Testing Market is Poised for Exponential Growth and is Expected to Reach USD 64,094.9 Million by 2030 | Infinium Global Research

Retrieved on: 
Thursday, October 12, 2023
Investment, Charles River Laboratories, Thermo Fisher Scientific, Molecular imaging, Government, Compound annual growth rate, Organization, USD, Safety, Movement, SGS, Abbott Laboratories, Perceived organizational support, Growth, Cosmetics, Toxicology, Merck Group, Eurofins Scientific, Agilent Technologies, Research, Medical device, Pharmaceutical industry

The in vitro toxicology testing market has been experiencing remarkable growth in recent years.

Key Points: 
  • The in vitro toxicology testing market has been experiencing remarkable growth in recent years.
  • The increasing demand for toxicology testing products propels the growth of the in vitro toxicology testing market.
  • Nonetheless, technological advancements in in vitro toxicology testing products create opportunities for companies operating in the market.
  • The global in vitro toxicology testing market is primed for substantial growth, driven by increasing government support, rising demand for toxicology testing products, and technological advancements.